Awaiting development: Guidance and quality standards
Showing 1 to 2 of 2
| Title | Type |
|---|---|
| Cobolimab with dostarlimab and docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy [ID6398] | Technology appraisal guidance |
| Dostarlimab for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency when systemic treatment is suitable [ID6660] | Technology appraisal guidance |